Financial Shenanigans

The Forensic Verdict

Cigna earns a 44 / 100, Elevated forensic risk score: the financials are cash-backed, but not clean enough to underwrite without a cash-flow and non-GAAP haircut. The top concerns are receivable factoring, liability timing, and recurring adjusted income measures that remove amortization and repeated special items. The cleanest offset is FY2025 operating cash flow of $9.6B against $6.0B of shareholders' net income, with PwC giving unqualified opinions on both the financial statements and internal control. The data point that would most change the grade is whether FY2026 cash flow remains above net income after factoring sales, unremitted collections, and pharmacy or insurance payables stop providing material timing support.

Breeding Ground

The breeding ground is not weak, but incentives and regulatory history amplify the accounting watch items. Cigna has a financially literate audit committee, no disclosed related-person transactions requiring SEC disclosure in 2025, no accountant disagreements, and effective internal control over financial reporting. The offset is that short- and long-term pay lean heavily on adjusted income and adjusted EPS, PwC has served since 1983, and the company resolved past Medicare Advantage risk-adjustment allegations in 2023 under a five-year Corporate Integrity Agreement.

Earnings Quality

Reported earnings are broadly earned, but revenue quality depends on PBM receivables, rebate estimates, and large soft assets. The accounting policy is not obviously aggressive on its face: retail PBM revenue is recognized when a pharmacy claim is processed and approved, home delivery and specialty revenue when prescriptions ship, premiums over the contract period, and rebates payable to clients reduce pharmacy revenue. The pressure point is not a hidden revenue model; it is that manufacturer and client receivables, contractual allowances, and non-GAAP exclusions are material.

Receivables are the first yellow flag. FY2025 receivables rose to $28.768B, up 18.7%, versus revenue growth of 11.2%; DSO rose to 35.2 days. The note detail matters: receivables were reported net of $6.8B of allowances, including $6.2B tied to contractual allowances for pharmaceutical manufacturer rebate receivables and $199M of expected credit loss allowance.

Margins do not scream earnings manipulation. Cigna's FY2025 operating margin was 3.3% and net margin was 2.2%, broadly in the managed-care peer range and below UnitedHealth on operating margin. This clean test matters because the receivable and adjustment concerns are not accompanied by implausible margin expansion.

Soft assets are large but not worsening. Goodwill plus intangibles were $73.5B in FY2025, or 46.5% of assets, down from 54.4% in FY2022. The annual impairment test reportedly supported fair values above carrying values by substantial margins, so this is an asset-quality watch item rather than evidence of current expense shifting.

Cash Flow Quality

Cash conversion is strong, but the mechanism is not simple recurring cash earnings. Over FY2023-FY2025, CFO was 2.18 times shareholders' net income and FCF was 1.81 times net income, which is a clean offset to the earnings-quality concerns. The forensic issue is that FY2024 and FY2025 CFO were materially shaped by receivable timing, factoring settlement timing, and pharmacy, accrued, and insurance liability movements.

The cash flow statement passes the first-order test. The problem is not weak CFO; the problem is sustainability. Management said FY2025 operating cash flow decreased primarily because of clients onboarded in 2024 and timing of settlements related to the accounts receivable factoring facility, partially offset by accrued liabilities and higher insurance liabilities.

The working-capital bridge is the most important cash-flow yellow flag. In FY2025, receivables consumed $4.630B of cash and inventory consumed $646M, while other operating activities contributed $5.477B. In FY2024, receivables consumed $7.369B and other operating activities contributed $9.593B, driven by items that include reinsurance recoverables and other assets, insurance liabilities, pharmacy and other service costs payable, accounts payable, accrued expenses, and other liabilities.

Acquisition-adjusted FCF remains positive, which keeps the grade out of High. FY2025 FCF after acquisitions was $6.093B, and FY2023-FY2025 cumulative FCF after acquisitions was $22.791B. The watch item is direction: FCF after acquisitions has stepped down from $9.033B in FY2023 to $7.665B in FY2024 and $6.093B in FY2025.

Metric Hygiene

Management's preferred metrics are disclosed and reconciled, but they are not neutral. Adjusted income from operations excludes net investment results, amortization of acquired intangibles, and special items; adjusted revenue excludes special items and certain equity-method investment results; adjusted SG&A excludes special items. Those definitions are consistent enough to model, yet recurring exclusions and incentive alignment mean GAAP and cash-flow bridges should drive valuation.

The FY2025 non-GAAP gap was $2.057B, or 34.5% of GAAP net income. The FY2024 gap was larger at $4.307B, mostly because the company excluded $2.529B of after-tax net investment losses. The repeated amortization exclusion is material by itself: $1.325B after tax in FY2025, $1.347B in FY2024, and $1.413B in FY2023.

Metric hygiene is the second-largest underwriting issue. The metrics are not hidden, and the reconciliation is adequate, but FY2025 compensation also used adjusted income, adjusted revenue growth, and adjusted EPS. That makes the adjustment bridge an economic input, not a footnote.

What to Underwrite Next

The next underwriting work should focus on cash-flow durability, receivable quality, and the adjusted-earnings bridge. The current accounting risk is not a thesis breaker, but it should affect valuation quality, position sizing, and the required margin of safety until the FY2026 cash-flow mechanism is cleaner.

Cigna's reported numbers appear usable, not pristine. The accounting risk is best treated as a valuation haircut and position-sizing limiter, not a thesis breaker: cash earnings are real, but the investor should underwrite a lower-quality multiple until receivables, factoring, supplier finance, liability timing, and repeated non-GAAP exclusions prove they are not carrying the story.